T2 Biosystems, Inc. (NASDAQ:TTOO) Q4 2020 Earnings Conference Call March 4, 2021 4:30 PM ET Company Participants Philip Taylor - Investor Relations, Gilmartin Group John Sperzel - President and CEO John Sprague - Chief Financial Officer Conference Call Participants Westley Dupray - SVB Leerink Max Masucci - Canaccord Genuity Mark Massaro - BTIG Ben Haynor - Alliance Global Partners Operator Greetings. Welcome to T2 Biosystems Fourth Quarter and Full Year 2020 Earnings Conference Call. At this time, all part ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36571 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 T2 Biosystems, Inc. (Exact name of registrant as specified in its charter) Delaware 20-4827488 (State or other jurisd ...

T2 Biosystems, Inc. (NASDAQ:TTOO) Q3 2020 Earnings Conference Call November 4, 2020 4:30 PM ET Company Participants Philip Taylor - Gilmartin Group John Sperzel - President and CEO John Sprague - CFO Conference Call Participants Max Masucci - Canaccord Genuity Puneet Souda - SVB Leerink Mark Massaro - BTIG Steve Brozak - WBB Securities Ben Haynor - Alliance Global Operator Greetings and welcome to the T2 Biosystems Third Quarter 2020 Earnings Conference Call. At this time, all participants are in a listen-o ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (Exact name of registrant as specified in its charter) Delaware 20-4827488 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 101 Hartwell Av ...

T2 Biosystems, Inc. (NASDAQ:TTOO) Q2 2020 Earnings Conference Call August 11, 2020 4:30 PM ET Company Participants Philip Taylor - Investor Relations John Sperzel - President & Chief Executive Officer John Sprague - Chief Financial Officer Tom Lowery - Chief Scientific Officer Conference Call Participants Puneet Souda - SVB Leerink Max Masucci - Canaccord Genuity Ben Haynor - Alliance Global Steve Brozak - WBB Securities Mark Massaro - BTIG Operator Greetings, and welcome to the T2 Biosystems Second Quarter ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FORM 10-Q For the quarterly period ended March 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36571 T2 Biosystems, Inc. (Exact name of registrant as specified in its charter) Delaware 20-4827488 (State or other jurisdicti ...

T2 Biosystems, Inc. (NASDAQ:TTOO) Q1 2020 Earnings Conference Call May 5, 2020 4:30 PM ET Company Participants Philip Taylor - IR John Sperzel - President and CEO John Sprague - CFO Tom Lowery - Chief Scientific Officer Tony Pare - Chief Commercial Officer Conference Call Participants Scott Mafale - SVB Leerink Patrick O'Donnell - Canaccord Genuity Ben Haynor - Alliance Global Steve Brozak - WBB Securities Operator Good day, everyone. Welcome to today’s T2 Biosystems First Quarter 2020 Earnings Conference C ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the year ended December 31, 2019 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36571 T2 Biosystems, Inc. (Exact name of registrant as specified in its charter) | Delaware | 20-4827488 | | --- | --- | | (State or other jur ...

Corporate Presentation Click to edit Master subtitle style Click to edit Master title (NASDAQ: TTOO) style February 2020 © 2020 T2 Biosystems. All Rights Reserved. 1 Forward-Looking Statements This presentation contains forward-looking statements. Such statements reflect the current views of senior management of T2 Biosystems, Inc. ("we", "us", "our", "T2", "T2 Biosystems" or the "Company") and include those about T2's goals, strategies, plans, objectives, prospects, milestones, future operations, business ...

T2 Biosystems, Inc. (NASDAQ:TTOO) Q4 2019 Results Conference Call February 24, 2020 4:30 PM ET Company Participants Philip Taylor - IR John Sperzel - President and CEO John Sprague - CFO Tony Pare - Chief Commercial Officer Tom Lowery - Chief Scientific Officer Conference Call Participants Mike Gokay - Janney Montgomery Scott Scott Mafale - SVB Leerink Ben Haynor - Alliance Global Steve Brozak - WBB Securities Soumit Roy - JonesTrading Operator Greetings. Welcome to the T2 Biosystems Fourth Quarter 2019 Res ...